Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP rose 8.9% on Wednesday . The stock traded as high as $8.29 and last traded at $8.27. Approximately 1,629,709 shares were traded during trading, an increase of 15% from the average daily volume of 1,411,901 shares. The stock had previously closed at $7.59.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.
Check Out Our Latest Analysis on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Down 1.5%
The company has a debt-to-equity ratio of 0.16, a current ratio of 5.93 and a quick ratio of 5.26. The stock has a market capitalization of $1.19 billion, a P/E ratio of 31.43 and a beta of 1.16. The firm has a 50-day simple moving average of $8.07 and a 200 day simple moving average of $8.07.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.08 by $0.08. The firm had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. On average, equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.
Hedge Funds Weigh In On Aurinia Pharmaceuticals
Several large investors have recently bought and sold shares of the company. US Bancorp DE raised its position in shares of Aurinia Pharmaceuticals by 61.9% during the fourth quarter. US Bancorp DE now owns 19,366 shares of the biotechnology company's stock worth $174,000 after acquiring an additional 7,406 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $25,000. Raymond James Financial Inc. bought a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $215,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Aurinia Pharmaceuticals by 22.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company's stock worth $4,997,000 after acquiring an additional 102,195 shares during the last quarter. Finally, Cibc World Markets Corp bought a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $113,000. 36.83% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
